Philadelphia chromosome positive
Information
- Disease name
- Philadelphia chromosome positive
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT01424982 | Active, not recruiting | Phase 2 | Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia | October 5, 2011 | October 31, 2025 |
| NCT03233854 | Active, not recruiting | Phase 1 | CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies | September 1, 2017 | September 1, 2035 |
| NCT02458014 | Active, not recruiting | Phase 2 | Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease | September 14, 2015 | September 30, 2024 |
| NCT01190930 | Active, not recruiting | Phase 3 | Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma | August 9, 2010 | March 31, 2028 |
| NCT03576547 | Active, not recruiting | Phase 1/Phase 2 | Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia | June 26, 2018 | August 31, 2024 |
| NCT00390793 | Completed | Phase 2 | Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. | September 28, 2006 | February 2, 2024 |
| NCT01043874 | Completed | Phase 4 | Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response | December 2009 | January 2014 |
| NCT05007873 | Recruiting | Phase 2 | ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase | October 21, 2021 | October 30, 2024 |
| NCT02997761 | Recruiting | Phase 2 | Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia | June 27, 2017 | September 2025 |
| NCT03241940 | Recruiting | Phase 1 | Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies | October 20, 2017 | August 1, 2035 |
| NCT03263572 | Recruiting | Phase 2 | Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia | November 29, 2017 | November 30, 2025 |
| NCT03512405 | Recruiting | Phase 1/Phase 2 | Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia | August 2, 2019 | October 30, 2024 |
| NCT03589729 | Recruiting | Phase 2 | Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers | September 19, 2018 | December 31, 2025 |
| NCT03698552 | Recruiting | Phase 1/Phase 2 | ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia | August 24, 2018 | December 31, 2025 |
| NCT03519984 | Terminated | Phase 1 | EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia | May 9, 2018 | November 24, 2020 |